Efficacy and safety of 1L selpercatinib in RET fusion-positive NSCLC: LIBRETTO-431 East Asian subgroup analysis.

被引:1
作者
Cheng, Ying [1 ]
Loong, Herbert H. [2 ]
Zhou, Caicun [3 ]
Nishino, Kazumi [4 ]
Lee, Dae Ho [5 ]
Lee, Se-Hoon [6 ]
Yang, James Chih-Hsin [7 ]
Liu, Dan [8 ]
Rajakumar, Deborah [9 ]
Han, Hongmei [10 ]
Puri, Tarun [11 ]
Lin, Aimee Bence [12 ]
Goto, Koichi
机构
[1] Jilin Canc Hosp, Changchun, Peoples R China
[2] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China
[3] Tongji Univ, Shanghai Pulm Hosp, Thorac Canc Inst, Dept Med Oncol,Sch Med, Shanghai, Peoples R China
[4] Osaka Int Canc Inst, Osaka, Japan
[5] Asan Med Ctr, Seoul, South Korea
[6] Sungkyunkwan Univ, Samsung Med Ctr, Dept Internal Med, Div Hematol Oncol,Sch Med, Seoul, South Korea
[7] Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[8] Natl Taiwan Univ Canc Ctr, Taipei, Taiwan
[9] LoxoLilly, Indianapolis, IN USA
[10] Eli Lilly UK, Bracknell, England
[11] Eli Lilly & Co, Indianapolis, IN USA
[12] Natl Canc Ctr Hosp East, Kashiwa, Japan
关键词
D O I
10.1200/JCO.2024.42.23_suppl.214
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页码:214 / 214
页数:1
相关论文
empty
未找到相关数据